Caroline de Mareüil-Villette is one of the two co-founders of ICOSA (France) and ICOSA Europe (Belgium), two Intellectual Property firms historically specialized in Life Sciences (Biology/Biotechnology, Chemistry) and Tech (Medical Devices, Artificial Intelligence/Software, Materials, Electronics).

Caroline holds degrees in Chemistry and Contracts Law. She is a European, French and Belgian Patent Attorney, and a UPC Representative. She also holds a diploma from CEIPI (Center for International Intellectual Property Studies).

Caroline de Mareüil-Villette is recognized for her expertise in IP strategy and the valuation of Intellectual Property assets. She advises a broad range of clients, including startups and investors, on IP audits and due diligence processes in preparation for fundraising rounds. In addition, she trains startup founders, R&D managers, and directors to raise awareness about the strategic importance of IP and to promote best practices that help avoid actions that could compromise patent protection.

She has been listed in the IAM Strategy 300 (The World’s Leading IP Strategists) since 2022.

A member of AIPPI and Co-Chair of the IP Valuation Committee within the Licensing Executives Society (LES), Caroline has also built an international network of patent attorneys and IP professionals with whom she collaborates closely.

Caroline began her career at the IP valorization subsidiary of the French National Center for Scientific Research (CNRS). She then joined a Monaco-based company specializing in cosmetic active ingredients, where she created and led the Patents & Contracts department. After spending three years in Princeton, NJ (USA), she worked for a Paris-based IP firm before joining one of France’s leading Intellectual Property firms in 2004, where she established a department dedicated to the financial valuation of patents, software, and trademarks.

To date, Caroline de Mareüil-Villette and her teams have advised over 700 French Healthtech startups on the protection and valorization of their IP assets, establishing ICOSA Group as a key player in the health innovation ecosystem in France and Belgium.

Recognized by the professional legal press, she is recommended in the IAM Patent 300 and 1000, MIP IPStars, and Legal 500 EMEA rankings.